454 related articles for article (PubMed ID: 28928007)
21. The effect of hemodialysis on balance measurements and risk of fall.
Erken E; Ozelsancak R; Sahin S; Yılmaz EE; Torun D; Leblebici B; Kuyucu YE; Sezer S
Int Urol Nephrol; 2016 Oct; 48(10):1705-11. PubMed ID: 27497737
[TBL] [Abstract][Full Text] [Related]
22. Cardiovascular risk factors in hemodialysis and peritoneal dialysis patients.
Helal I; Smaoui W; Hamida FB; Ouniss M; Aderrahim E; Hedri H; Elyounsi F; Maiz HB; Abdallah TB; Kheder A
Saudi J Kidney Dis Transpl; 2010 Jan; 21(1):59-62. PubMed ID: 20061694
[TBL] [Abstract][Full Text] [Related]
23. [The effect of hemodialysis on some parameters of the antioxidant system in the blood of patients with chronic renal failure].
Olszewska M
Ann Acad Med Stetin; 2004; 50(1):41-52. PubMed ID: 16871743
[TBL] [Abstract][Full Text] [Related]
24. Rationale for a New Classification of Solutes of Interest in Chronic Kidney Disease and Hemodialysis.
Reis T; Hutchison C; de Assis Rocha Neves F; Zawadzki B; Zanella M; Ronco C; Rosner MH
Blood Purif; 2023; 52(3):242-254. PubMed ID: 36657410
[TBL] [Abstract][Full Text] [Related]
25. Effect of Different Hemodialysis Methods on Microbiota in Uremic Patients.
He H; Xie Y
Biomed Res Int; 2020; 2020():6739762. PubMed ID: 32685517
[TBL] [Abstract][Full Text] [Related]
26. Acute effects of hemodialysis on lung function in patients with end-stage renal disease.
Lang SM; Becker A; Fischer R; Huber RM; Schiffl H
Wien Klin Wochenschr; 2006 Mar; 118(3-4):108-13. PubMed ID: 16703255
[TBL] [Abstract][Full Text] [Related]
27. Plasma aminothiol oxidation in chronic hemodialysis patients.
Himmelfarb J; McMenamin E; McMonagle E
Kidney Int; 2002 Feb; 61(2):705-16. PubMed ID: 11849414
[TBL] [Abstract][Full Text] [Related]
28. Protection of Residual Renal Function and Nutritional Treatment: First Step Strategy for Reduction of Uremic Toxins in End-Stage Kidney Disease Patients.
Cupisti A; Bolasco P; D'Alessandro C; Giannese D; Sabatino A; Fiaccadori E
Toxins (Basel); 2021 Apr; 13(4):. PubMed ID: 33921862
[TBL] [Abstract][Full Text] [Related]
29. Red blood cell calcium homeostasis in patients with end-stage renal disease.
Gafter U; Malachi T; Barak H; Djaldetti M; Levi J
J Lab Clin Med; 1989 Sep; 114(3):222-31. PubMed ID: 2527934
[TBL] [Abstract][Full Text] [Related]
30. Mass spectrometric monitoring of albumin in uremia.
Thornalley PJ; Argirova M; Ahmed N; Mann VM; Argirov O; Dawnay A
Kidney Int; 2000 Nov; 58(5):2228-34. PubMed ID: 11044246
[TBL] [Abstract][Full Text] [Related]
31. Pharmacokinetics of mycophenolate mofetil in patients with end-stage renal failure.
MacPhee IA; Spreafico S; Bewick M; Davis C; Eastwood JB; Johnston A; Lee T; Holt DW
Kidney Int; 2000 Mar; 57(3):1164-8. PubMed ID: 10720968
[TBL] [Abstract][Full Text] [Related]
32. The optimal timing of hemoperfusion component in combined hemodialysis-hemoperfusion treatment for uremic toxins removal.
Li J; Li D; Xu Y; Wang A; Xu C; Yu C
Ren Fail; 2015 Feb; 37(1):103-7. PubMed ID: 25421427
[TBL] [Abstract][Full Text] [Related]
33. HPLC study of uremic fluids related to optical dialysis adequacy monitoring.
Lauri K; Tanner R; Jerotskaja J; Luman M; Fridolin I
Int J Artif Organs; 2010 Feb; 33(2):96-104. PubMed ID: 20306436
[TBL] [Abstract][Full Text] [Related]
34. Arterial stiffness in predialysis patients with uremia.
Shinohara K; Shoji T; Tsujimoto Y; Kimoto E; Tahara H; Koyama H; Emoto M; Ishimura E; Miki T; Tabata T; Nishizawa Y
Kidney Int; 2004 Mar; 65(3):936-43. PubMed ID: 14871413
[TBL] [Abstract][Full Text] [Related]
35. Challenges of reducing protein-bound uremic toxin levels in chronic kidney disease and end stage renal disease.
Faria M; de Pinho MN
Transl Res; 2021 Mar; 229():115-134. PubMed ID: 32891787
[TBL] [Abstract][Full Text] [Related]
36. Paraoxonase-1 concentrations in end-stage renal disease patients increase after hemodialysis: correlation with low molecular AGE adduct clearance.
Gugliucci A; Mehlhaff K; Kinugasa E; Ogata H; Hermo R; Schulze J; Kimura S
Clin Chim Acta; 2007 Feb; 377(1-2):213-20. PubMed ID: 17118352
[TBL] [Abstract][Full Text] [Related]
37. Antithrombin deficiency in end-stage renal disease associated with paraplegia: effect of hemodialysis.
Vaziri ND; Winer RL; Alikhani S; Danviryasup K; Toohey J; Hung E; Gordon S; Eltorai I; Paule P
Arch Phys Med Rehabil; 1985 May; 66(5):307-9. PubMed ID: 3924003
[TBL] [Abstract][Full Text] [Related]
38. Uremic solutes and risk of end-stage renal disease in type 2 diabetes: metabolomic study.
Niewczas MA; Sirich TL; Mathew AV; Skupien J; Mohney RP; Warram JH; Smiles A; Huang X; Walker W; Byun J; Karoly ED; Kensicki EM; Berry GT; Bonventre JV; Pennathur S; Meyer TW; Krolewski AS
Kidney Int; 2014 May; 85(5):1214-24. PubMed ID: 24429397
[TBL] [Abstract][Full Text] [Related]
39. [The Veneto Region's Registry of Dialysis and Transplantation: 2006-2007 report].
Antonucci F; Camerin E; Feriani M; Nordio M; Piccoli A; Rossi B; Tessitore N
G Ital Nefrol; 2009; 26 Suppl 48():S5-56. PubMed ID: 19927265
[TBL] [Abstract][Full Text] [Related]
40. Plasma catecholamines, neuropeptide Y and leucine-enkephalin in uremic patients before and after dialysis during rest and handgrip.
Klin M; Waluga M; Rudka R; Madej A; Janiszewska M; Grzebieniak E; Wesolowky A
Boll Chim Farm; 1998 Sep; 137(8):306-13. PubMed ID: 9835145
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
